000258697 001__ 258697
000258697 005__ 20240112171702.0
000258697 0247_ $$2doi$$a10.1002/alz.13012
000258697 0247_ $$2pmid$$apmid:36905286
000258697 0247_ $$2ISSN$$a1552-5260
000258697 0247_ $$2ISSN$$a1552-5279
000258697 0247_ $$2altmetric$$aaltmetric:143756763
000258697 037__ $$aDZNE-2023-00670
000258697 041__ $$aEnglish
000258697 082__ $$a610
000258697 1001_ $$0P:(DE-2719)9001238$$aPlaten, Moritz$$b0$$eFirst author$$udzne
000258697 245__ $$aImpact of low-value medications on quality of life, hospitalization and costs - A longitudinal analysis of patients living with dementia.
000258697 260__ $$aHoboken, NJ$$bWiley$$c2023
000258697 3367_ $$2DRIVER$$aarticle
000258697 3367_ $$2DataCite$$aOutput Types/Journal article
000258697 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1697111603_28730
000258697 3367_ $$2BibTeX$$aARTICLE
000258697 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000258697 3367_ $$00$$2EndNote$$aJournal Article
000258697 520__ $$aThis study aimed to analyze the impact of low-value medications (Lvm), that is, medications unlikely to benefit patients but to cause harm, on patient-centered outcomes over 24 months.This longitudinal analysis was based on baseline, 12 and 24 months follow-up data of 352 patients with dementia. The impact of Lvm on health-related quality of life (HRQoL), hospitalizations, and health care costs were assessed using multiple panel-specific regression models.Over 24 months, 182 patients (52%) received Lvm at least once and 56 (16%) continuously. Lvm significantly increased the risk of hospitalization by 49% (odds ratio, confidence interval [CI] 95% 1.06-2.09; p = 0.022), increased health care costs by €6810 (CI 95% -707€-14,27€; p = 0.076), and reduced patients' HRQoL (b = -1.55; CI 95% -2.76 to -0.35; p = 0.011).More than every second patient received Lvm, negatively impacting patient-reported HRQoL, hospitalizations, and costs. Innovative approaches are needed to encourage prescribers to avoid and replace Lvm in dementia care.Over 24 months, more than every second patient received low-value medications (Lvm). Lvm negatively impact physical, psychological, and financial outcomes. Appropriate measures are needed to change prescription behaviors.
000258697 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000258697 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000258697 650_7 $$2Other$$aAlzheimer's disease
000258697 650_7 $$2Other$$adementia
000258697 650_7 $$2Other$$ahealth care costs
000258697 650_7 $$2Other$$ahealth care resources
000258697 650_7 $$2Other$$ahealth-related quality of life
000258697 650_7 $$2Other$$ahospitalization
000258697 650_7 $$2Other$$alow-value care
000258697 650_2 $$2MeSH$$aHumans
000258697 650_2 $$2MeSH$$aQuality of Life
000258697 650_2 $$2MeSH$$aHealth Care Costs
000258697 650_2 $$2MeSH$$aHospitalization
000258697 650_2 $$2MeSH$$aDementia: drug therapy
000258697 7001_ $$0P:(DE-HGF)0$$aFlessa, Steffen$$b1
000258697 7001_ $$0P:(DE-2719)2000026$$aTeipel, Stefan$$b2$$udzne
000258697 7001_ $$0P:(DE-2719)9001134$$aRädke, Anika$$b3$$udzne
000258697 7001_ $$0P:(DE-2719)9001251$$aScharf, Annelie$$b4$$udzne
000258697 7001_ $$0P:(DE-2719)9001321$$aMohr, Wiebke$$b5$$udzne
000258697 7001_ $$0P:(DE-2719)9002138$$aBuchholz, Maresa$$b6$$udzne
000258697 7001_ $$0P:(DE-2719)2000040$$aHoffmann, Wolfgang$$b7$$udzne
000258697 7001_ $$0P:(DE-2719)2810763$$aMichalowsky, Bernhard$$b8$$eLast author$$udzne
000258697 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz.13012$$gp. alz.13012$$n10$$p4520 - 4531$$tAlzheimer's and dementia$$v19$$x1552-5260$$y2023
000258697 8564_ $$uhttps://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.13012
000258697 8564_ $$uhttps://pub.dzne.de/record/258697/files/DZNE-2023-00670.pdf$$yOpenAccess
000258697 8564_ $$uhttps://pub.dzne.de/record/258697/files/DZNE-2023-00670.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000258697 909CO $$ooai:pub.dzne.de:258697$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000258697 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001238$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000258697 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000026$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000258697 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001134$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000258697 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001251$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000258697 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001321$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000258697 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002138$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000258697 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000258697 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810763$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000258697 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000258697 9141_ $$y2023
000258697 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000258697 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000258697 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-11$$wger
000258697 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-11
000258697 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-11
000258697 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000258697 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000258697 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000258697 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000258697 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000258697 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000258697 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2023-10-25
000258697 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x0
000258697 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x1
000258697 9201_ $$0I:(DE-2719)1510800$$kAG Thyrian$$lInterventional Health Care Research (IHCR)$$x2
000258697 9201_ $$0I:(DE-2719)5000067$$kAG Michalowsky ; AG Michalowsky$$lAG Michalowsky$$x3
000258697 980__ $$ajournal
000258697 980__ $$aVDB
000258697 980__ $$aI:(DE-2719)1510600
000258697 980__ $$aI:(DE-2719)1510100
000258697 980__ $$aI:(DE-2719)1510800
000258697 980__ $$aI:(DE-2719)5000067
000258697 980__ $$aUNRESTRICTED
000258697 9801_ $$aFullTexts